FALLACARA, ANNA LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 1.094
EU - Europa 782
AS - Asia 152
SA - Sud America 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.034
Nazione #
US - Stati Uniti d'America 1.091
GB - Regno Unito 253
IE - Irlanda 154
IT - Italia 105
CN - Cina 84
SE - Svezia 65
UA - Ucraina 61
RU - Federazione Russa 53
FR - Francia 40
SG - Singapore 31
DE - Germania 26
VN - Vietnam 11
FI - Finlandia 10
TR - Turchia 6
CZ - Repubblica Ceca 5
ES - Italia 4
IN - India 4
JP - Giappone 4
CA - Canada 3
NL - Olanda 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
BR - Brasile 2
CI - Costa d'Avorio 2
IR - Iran 2
BD - Bangladesh 1
BO - Bolivia 1
EU - Europa 1
HK - Hong Kong 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
KZ - Kazakistan 1
PH - Filippine 1
PT - Portogallo 1
TH - Thailandia 1
Totale 2.034
Città #
Southend 237
Fairfield 176
Dublin 152
Woodbridge 94
Chandler 90
Siena 78
Houston 74
Seattle 69
Ashburn 68
Wilmington 62
Cambridge 61
Jacksonville 59
Menlo Park 45
Ann Arbor 33
New York 29
Princeton 26
Singapore 25
Beijing 21
Nanjing 19
Dearborn 15
Phoenix 14
San Diego 13
Boardman 11
Dong Ket 11
Nanchang 8
San Mateo 7
Milan 6
Paris 6
Shenyang 6
Fremont 5
Hebei 5
Jinan 5
Shanghai 5
Brno 4
Helsinki 4
Izmir 4
Los Angeles 4
Norwalk 4
Venezia 4
Düsseldorf 3
London 3
Moscow 3
Munich 3
Málaga 3
Tianjin 3
Abidjan 2
Brussels 2
Changsha 2
Manchester 2
Newark 2
Padova 2
San Francisco 2
Taizhou 2
Toronto 2
Utrecht 2
Yenibosna 2
Almaty 1
Amman 1
Baghdad 1
Chiswick 1
Clearwater 1
Dallas 1
Dello 1
Dhaka 1
Dubai 1
Garching 1
Groningen 1
Haifa 1
Hefei 1
Hong Kong 1
Hounslow 1
Jiaxing 1
Kunming 1
Lancaster 1
Madrid 1
Manila 1
Mestre 1
Ningbo 1
Oklahoma City 1
Poggibonsi 1
Prague 1
Prescot 1
Quzhou 1
Redwood City 1
Santa Clara 1
Sucre 1
São Paulo 1
Tokyo 1
Washington 1
Zanjan 1
Totale 1.633
Nome #
Prodrugs of pyrazolo[3,4-d]pyrimidines: from library synthesis to evaluation as potential anticancer agents in an orthotopic glioblastoma model 267
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor 219
Pyrazolo[3,4-d]pyrimidines-loaded human serum albumin (HSA) nanoparticles: preparation, characterization and cytotoxicity evaluation against neuroblastoma cell line 213
4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling 196
Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction 157
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment 156
Protein-protein interactions and human cellular cofactors as new targets for HIV therapy 139
Insight into the Allosteric Inhibition of Abl Kinase 136
Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors 119
Inhibitors of tau-phosphorylating kinases 117
One-pot synthesis of spiro(indoline-3,4′-pyrazolo[3,4-b]pyridine)-5′-carbonitriles as p53-MDM2 interaction inhibitors 110
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines 104
null 82
3-Arylidene-N-hydroxyoxindoles: A New Class of Compounds Endowed with Antitumor Activity 48
The Pyrazolo[3,4-d]Pyrimidine Derivative Si306 Encapsulated into Anti-GD2-Immunoliposomes as Therapeutic Treatment of Neuroblastoma 19
Totale 2.082
Categoria #
all - tutte 6.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.047


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020333 0 0 0 0 44 46 51 62 51 32 24 23
2020/2021294 9 31 6 28 19 33 9 43 19 50 21 26
2021/2022243 22 34 8 4 13 3 14 3 10 45 34 53
2022/2023276 17 35 30 33 31 40 12 24 35 9 7 3
2023/2024253 10 3 10 15 7 80 82 15 0 5 17 9
2024/2025109 10 18 51 20 10 0 0 0 0 0 0 0
Totale 2.082